Resverlogix Corp. RVX.TO
Set alert
As of Nov 2, 3:47 PM ET
- YTD
- -25.00%
- 1 year
- -21.05%
- Open
- 0.075
- Prev close
- 0.075
- Mkt cap
- 25.82M
- Vol
- 4.00K
- Avg vol
- 23.89K
- EPS
- -0.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.075
- High
- 0.075
- Forward P/E
- -0.25
- Beta
- 0.00
- Short ratio
- 0.61
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.0632
- 200-d avg
- 0.0623
- 1y target
- 0.00
2Y chart
Signals (135)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 27, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
Newest 20 of 135.
Key statistics
- Market cap
- 15.44M
- Enterprise value
- 80.30M
- Trailing P/E
- 0.00
- Forward P/E
- -0.25
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.06
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 12.29M
- Total cash
- 43.00K
- Total debt
- 65.25M
- Return on equity
- 0.00%
- Shares outstanding
- 280.65M
- Short % of float
- 0.00%
- 50-day average
- 0.0632
- 200-day average
- 0.0623
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- resverlogix.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on RVX.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Captrust Financial Advisors | 0.00% | 4,000 | 219 | Jun 29, 2022 |